Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 92(3): 295-302, 2021 03.
Article
in En
| MEDLINE
| ID: mdl-33184094
ABSTRACT
OBJECTIVE:
To establish a rigorous, expert-led, evidence-based approach to the evaluation of licensed drugs for repurposing and testing in clinical trials of people with progressive multiple sclerosis (MS).METHODS:
We long-listed licensed drugs with evidence of human safety, blood-brain barrier penetrance and demonstrable efficacy in at least one animal model, or mechanistic target, agreed by a panel of experts and people with MS to be relevant to the pathogenesis of progression. We systematically reviewed the preclinical and clinical literature for each compound, condensed this into a database of summary documents and short-listed drugs by scoring each one of them. Drugs were evaluated for immediate use in a clinical trial, and our selection was scrutinised by a final independent expert review.RESULTS:
From a short list of 55 treatments, we recommended four treatments for immediate testing in progressive MS R-α-lipoic acid, metformin, the combination treatment of R-α-lipoic acid and metformin, and niacin. We also prioritised clemastine, lamotrigine, oxcarbazepine, nimodipine and flunarizine.CONCLUSIONS:
We report a standardised approach for the identification of candidate drugs for repurposing in the treatment of progressive MS.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Multiple Sclerosis, Chronic Progressive
/
Drug Repositioning
Type of study:
Prognostic_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
J Neurol Neurosurg Psychiatry
Year:
2021
Document type:
Article
Affiliation country:
United kingdom
Publication country:
ENGLAND
/
ESCOCIA
/
GB
/
GREAT BRITAIN
/
INGLATERRA
/
REINO UNIDO
/
SCOTLAND
/
UK
/
UNITED KINGDOM